EMA publishes new Q&A Document on Remote RP Activities
Recommendation

22 October 2026
Good Distribution Practice of Active Substances for Human and Veterinary Medicinal Products
The European Medicines Agency (EMA) provides answers to frequently asked questions on Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP) on its website, which have been compiled and agreed by the GMP/GDP Inspectors Working Group.
Now, a new PDF file on Remote RP activities in English language was published. The document was made available on 18 April 2024 in the subsection on GDP requirements.
The document was prepared against the background that a recurring observation made in GDP inspections was that certain RP activities are delegated to employees located outside of the EU/EEA.
According to the document, remote activities by the Responsible Person "could be allowed if accepted by the national competent authority where the authorised site is located", however "RP activities should take place within the EU/EEA (or Northern Ireland) in all cases". In other words, "any RP activities being carried out by a person localised and employed in a country outside of the union should not be accepted."
As there may be country specific rules, it is recommended that wholesalers should consult with their national competent authority in order to determine what requirements apply.
For further information, please see the complete PDF file.
Related GMP News
30.09.2026European GDP Association Developments May through August 2026
30.09.2026Warehouse Temperature Excursions: What Does the FDA Expect?
30.09.2026Version 4.0 of the Swissmedic Document on Notifications of Changes Published
30.09.2026USA: Court Stops Warehouse Activities Following Persistent Insanitary Warehouse Conditions
30.09.2026GDP Non-Compliance Report: CAPA Measures must not only be Promised but also Implemented
10.09.2026Reminder: Submit your Presentation Proposal for the GDP Forum 2027 by 30 September


